NewsRoom Articles - Page 43 of 45

MondayJun 27, 2022 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Reach of its Drug Delivery Technology Through Newly Inked Agreements with Beverage Developer BevNology

Drug delivery technology innovator Lexaria Bioscience has developed a patented technology showing superiority in animal and human testing as a means of improving existing drug brands’ performance and establishing new solutions for unmet medical needsThe company recently announced agreements with beverage developer BevNology to expand production capabilities for Lexaria's own growing list of B2B clientele and empowering BevNology to offer DehydraTECH products with active ingredients derived from hemp including CBD under BevNology and partnered brands The technology is called DehydraTECH — improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery Lexaria also recently announced an…

FridayJun 24, 2022 12:00 pm

Hope of Herd Immunity Dwindles Alongside Federal COVID-19 Budget and Supplies; Aditxt Inc. (NASDAQ: ADTX) and AditxtScore(TM) Could Create Map to COVID-19 Immune Responses

Two years after a vaccine was made available for COVID-19, fewer than 70% of Americans have been vaccinatedThe AditxtScore(TM) can provide the necessary answers to individualized immune response questions and direct on the best course of treatment for the individual – not the herdNo additional funding for COVID-19 relief has been approved by Congress, requiring the Biden Administration to reallocate funds to prepare for the fall months and uptick in virus countsThe reallocation of funds for further vaccine development has reduced the amount spent on testing efforts causing concern for epidemiologists due to the lack of variant tracking The COVID-19…

FridayJun 24, 2022 11:15 am

Flora Growth Corp. (NASDAQ: FLGC) Authorizes the Repurchase of up to $5 Million Shares

Flora Growth Corp. announced that the Company Board has authorized the repurchase of up to $5 million of its outstanding common sharesLuis Merchan, Flora’s Chairman and CEO, said that Flora is executing its growth plans while simultaneously improving gross profit margins and reducing corporate overhead expensesAt the closing of 2021, the company announced a 2022 revenue guidance projection of $35-45 million Flora Growth (NASDAQ: FLGC) is a global leader in the cultivation, marketing, and distribution of premium-quality cannabis products and brands at below-market prices. Flora Growth recently announced that the company’s Board of Directors (the "Board") has authorized the repurchase…

ThursdayJun 23, 2022 10:30 am

Golden Matrix Group Inc.’s (NASDAQ: GMGI) AI-Powered I-Gaming Systems Fuel Revenue Growth Despite Looming Recession

Online gambling growing despite recession fears, expected to reach $115.13 billion by 2026 at CAGR of 9.2% GMGI leads industry with modular, turnkey, and white label gaming platforms compatible with all major browsers, operating systems, devicesGM-X gaming systems collect player data, leverage AI algorithms to enhance gaming experience, increase player retention, boost B2B client profitability Online gambling continues to grow globally and is expected to reach $81.08 billion in 2022 at a compound annual growth rate (“CAGR”) of 10.4% (https://ibn.fm/CqiDg). Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems, and gaming content, leads the industry with…

ThursdayJun 23, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grants Licenses to Three Companies for the Month of June; Looks to Follow Through with its Scheduled 2022 Clinical Studies

Lexaria sold Premier Wellness Science Co. exclusive rights to use its patented DehyraTECH(TM) in Japan in a variety of CBD productsValcon Medical A/S also signed an agreement with Lexaria to use its platform for medical cannabis applications in EuropeAnodGen Bioceuticals received a pharmaceutical license to use the platform for manufacturing and distributing CBD API powders in Europe, Australia, and New Zealand Lexaria Bioscience (NASDAQ: LEXX) kicked off the month by announcing an exclusive license to Premier Wellness Science Co. for the use of its patented DehydraTECH(TM) technology in Japan in a variety of CBD products. Announced on June 3, this…

WednesdayJun 22, 2022 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Closes the First Half of 2022 with UK Product Launch, Successful Brand Acquisition, and a Collaboration with Ricky Williams’ Cannabis Brand, Highsman

Flora’s collaboration with Highsman seeks to elevate both Highsman and Vessel, Flora’s accessories brand, thereby inspiring greatness and creating an experience worth sharingThe company’s acquisition of Masaya allows it to deliver on its promise to invest in safe, thorough, and cutting-edge cannabis researchFlora’s product launch on Amazon.co.uk marks a big step in operations expansion in Europe The first half of 2022 has been successful for Flora Growth (NASDAQ: FLGC). At the beginning of the year, the company’s management noted how the cannabis sector was ripe for the picking. They noted how great brands and cost advantages are optimal traits for…

TuesdayJun 21, 2022 9:45 am

Expanding Array of API Enhancements Through Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented Drug Technology Bodes Well for New Patient Solutions

Drug bioavailability enhancement technology developer Lexaria Bioscience is working to increase the number of potential new solutions to unmet medical needs and improving existing treatments for other chronic conditionsLexaria’s patented DehydraTECH solution transforms a wide variety of orally and topically administered products into enhanced solutions that make the active pharmaceutical ingredients (“APIs”) more rapidly available and effective at lower doses DehydraTECH-enhanced products have also demonstrated the ability to cross the blood-brain barrier through fatty acid transport proteins The company’s ongoing series of tests of different DehydraTECH-enhanced products has led to a pre-IND filing with the FDA for a prospective registered treatment for…

FridayJun 17, 2022 9:45 am

Golden Matrix Group Inc. (NASDAQ: GMGI) Focused on Growing Out Their B2B and B2C Verticals

Golden Matrix Group, Inc has been a major beneficiary of the growth in online gaming as well as the ongoing regulation and legalization of online casinos and online sports betting GloballyThe Company has expanded its white-label B2B offering through the launch of the GM-X and GM-Ag turnkey solution, a complete software package designed to allow land-based operators to transition into providing online operationsGMGI have separately sought to bolster their B2C offering, most recently through the acquisition of a controlling stake in UK-based RKingsCompetitions, a leading online competition company in the UK and Northern IrelandIn addition to contributing over $5.1 million…

FridayJun 17, 2022 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Achieves Key Milestone in Global Expansion Plan with JustCBD Launch on Amazon UK

Flora Growth completed the acquisition of Just Brands LLC and High Roller Private Label LLC, owners of the JustCBD brand, on February 28, 2022The company then expanded its operational footprint in Europe and the UK in May 2022 to further its international growth strategyJustCBD products, including gummies and tinctures, will be available on www.Amazon.co.uk starting this month in a pilot-only programFlora Growth is optimistic that this launch will allow the company to reach a larger consumer base as it works towards further expanding its operations across Europe On February 28, 2022, Flora Growth (NASDAQ: FLGC) completed the acquisition of 100%…

WednesdayJun 15, 2022 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Initiates Communication with the FDA Concerning Potential Treatment for Hypertension; Out-Licenses Its DehydraTECH Technology to International Markets

Lexaria, a global innovator of drug delivery platforms, recently filed a pre-IND meeting request letter with the FDA, initiating communication regarding the development of its DehydraTECH-CBD as a treatment for hypertensionThe company has been undertaking preparatory programs in readiness for the meeting, as well as an IND application filingThe pre-IND meeting will confirm the details of the company’s IND-enabling programLexaria also announced it had licensed its DehydraTECH technology to AnodGen, with the announcement following similar out-licensing agreements with Valcon Medical and Premier Science Early last September, global innovator Lexaria Bioscience (NASDAQ: LEXX) was pleased to announce it had formally commenced the process…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000